{"id":"placebo-for-cab-la","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert formulations used in randomized controlled trials to provide a baseline against which the effects of an active drug can be measured. In this Phase 3 trial for CAB LA (cabotegravir long-acting), the placebo arm allows researchers to distinguish genuine drug effects from natural disease progression, spontaneous remission, or psychological effects. Placebo responses help establish the true clinical benefit of the investigational treatment.","oneSentence":"A placebo control contains no active pharmaceutical ingredient and serves as a comparator in clinical trials to establish the efficacy of the active investigational drug.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:22.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 trial for cabotegravir long-acting (CAB LA) in HIV prevention or treatment"}]},"trialDetails":[{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT03164564","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-11-07","conditions":"HIV Infections","enrollment":3224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo for long acting cabotegravir"],"phase":"phase_3","status":"active","brandName":"Placebo for CAB LA","genericName":"Placebo for CAB LA","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo control contains no active pharmaceutical ingredient and serves as a comparator in clinical trials to establish the efficacy of the active investigational drug. Used for Control arm in Phase 3 trial for cabotegravir long-acting (CAB LA) in HIV prevention or treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}